Studien und Publikationen

ECCMID 2015 - P0566/ Comparison of the new Hologic Aptima HIV-1 Quant Dx Assay with the established Abbott RealTime in HIV-1 viral load measurement

EMMD Nordwijk 2015 - The newly developed Cepheid Xpert® HIV-1 VL compared to the established Abbott RealTime HIV-1 viral load measurement

EMMD Nordwijk 2015 - Hologic Aptima HIV-1 Quant Dx Assay Compared to Abbott RealTime in B and non-B Subtypes in daily routine testing

ECCMID 2016 - P0046/ Comparison of the recently launched Hologic Aptima HCV Quant Dx assay with the established Abbott RealTime HCV assay in viral load measurement.

CROI 2016 - 525/ Comparison of Four HCV Viral Load Assays at High Viral Load

ESCV Lissabon 2016 - PP40/ Comparison of the recently launched Hologic Aptima HBV Quant assay with the established Abbott RealTime HBV assay in viral load measurement

eurDrugRes Rom 2016 - O-04/ Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population proportions

HIV Glasgow 2016 - P358/ Frequency of additional resistance relevant mutations in 2% and 1% population proportions in next generation sequencing in routine HIV-1 resistance diagnostics

ECCMID 2017 - P1838/ Comparison of the Hologic Aptima HIV-1 Quant Dx Assay with the Abbott RealTime and Roche Cobas 6800 in simultaneously HIV -1 viral load measurement focussing low end detection.

EACS 2017 - PE6/25/ NGS in routine HIV-1 resistance diagnostic-frequency of additional resistance relevant mutationsin 2% and 1% population proportions correlated toviral load and additional patient follow-ups

GfV 2019 - Establishment of anti-Hepatitis C Virus IgG Avidity Test for Dried Serum/Plasma Spots

ECCMID 2019 - P1689/ Mycoplasma genitalium resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG & AziR Assay

EMMD 2019 - 48/ Integrating genotypic HIV tropism testing into the Vela Sentosa HIV genotyping and resistance assay

GfV 2019 - P60/ Comparison of the new Cepheid HIV VL XC Assay with the established Abbott Alinity m in HIV-1 viral load measurement

ECCMID 2021 - 03132/ Performance of Abbott Alinity m and RealTime SARS-CoV-2 assays in clinical practice

ECCMID 2021 - 04241/ Performance comparison of the Hologic Aptima SARS-CoV-2 assay with the Abbott RealTime, the Abbott Alinity m and an inhouse SARS-CoV-2 assay

ECCMID 2021 - 03002/ Comparison of the new Cepheid HIV VL XC Assay with the established Abbott Alinity m in HIV-1 viral load measurement

ESCV 2021 - P176/ Performance of the new Abbott Realtime SARS-CoV-2 assay

ESCV 2021 - P160/ Evaluation of the new Alinity m Resp-4-Plex assay

ESCV 2021 - P048/ Comparison of the Alinity m system with the established Abbott RealTime and Hologic Aptima Quant Assay in HIV-1, HCV and HBV viral load measurement

ESCV 2021 - P076/ No impact on HIV-1 quantification by the Alinity m HIV-1 assay due to mutations in the HIV-1 integrase gene

ESCV 2021 - P159/ Pool testing from throat wash and nasopharyngeal swabs for SARS-CoV-2 RNA with high sensitivity

ECCMID 2022 - P2216/ SARS-CoV-2antibody levels after vaccination and booster in different vaccination regimen

ESCV 2022 - PP-221/ Antibody levels against SARS-CoV-2 after vaccination and booster in different vaccination regimens

ESCV 2022 - PP-146/ Evaluation of the performance of the high-throughput multiplex Alinity m Resp-4-Plex assay